Zydus Cadila gets USFDA nod for kidney stones tablets

Tags: Companies
Drug firm Zydus Cadila has received the final approval from the US health regulator to market Potassium Citrate ER tablets used in prevention of kidney stones.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Potassium Citrate ER tablets in the strengths of 5 mEq, 10 mEq and 15 mEq, said the Zydus group's listed entity, Cadila Healthcare, said in a statement.

"The estimated sales in 2014 for Potassium Citrate ER tablets is $131.7 million, as per IMS," it added.

The group currently has 94 approvals and has so far filed 239 abbreviated new drug applications (ANDA), Cadila Healthcare said.

Shares of Cadila Healthcare were trading at Rs 1,098.95 per scrip in the afternoon trade on the BSE, up 0.35% from the previous close.

EDITORIAL OF THE DAY

  • Nothing short of a uniform civil code will work in India

    When the Jamiat-Ulama-I-Hind (JUH), a powerful body of muslim clerics dedicated to address the aspirations of the community, turns to quote the religi

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

A democracy must stand up for its people

We are the world’s most populous dem­ocracy, but behave in ...

Purnendu Ghosh

A curious and an innovative mind

Curiosity is hard-wired into our psyche. We all recognise that ...

Shona Adhikari

A good time for European art auctions

This week, we bring you interesting art news and the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture